Information Provided By:
Fly News Breaks for December 16, 2019
Dec 16, 2019 | 08:11 EDT
Credit Suisse analyst A.J. Rice says he believes Mednax could be an attractive target for private equity in the $35-$36 per share range. Although other physician outsourcing companies have struggled in the debt markets post-LBO, Mednax s being valued at a substantially lower valuation and has what is generally considered stable assets, such as its industry-leading women's/children's and NICU business and a growing tele-radiology business, Rice tells investors in a research note. He keeps an Outperform rating and $33 price target on the shares.
News For MD From the Last 2 Days
There are no results for your query MD